- « Previous
- Clinical Pharmacology
- Next »
Elaprase
Clinical Pharmacology
Elaprase
Examination of the individual components of the composite score showed that, in the adjusted analysis, the weekly ELAPRASE-treated group experienced a 35 meter greater mean increase in the distance walked in six minutes compared to placebo. The changes in %-predicted FVC were not statistically significant (Table 2).
Table 2 - Clinical Study Results
| ELAPRASE Weekly n=32a |
Placebo n=32a |
ELAPRASE Weekly - Placebo |
|||||
| Baseline | Week 53 | Changeb | Baseline | Week 53 | Changeb | Difference in Change |
|
| Results from the 6-Minute Walk Test (Meters) | |||||||
| Mean ± SD | 392 ± 108 | 436 ± 138 | 44 ± 70 | 393 ± 106 | 400 ± 106 | 7 ± 54 | 37 ± 16c 35 ± 14d (p=0.01) |
| Median | 397 | 429 | 31 | 403 | 412 | -4 | |
| Percentiles (25th, 75th) | 316, 488 | 365, 536 | 0, 94 | 341, 469 | 361, 460 | -30, 31 | |
| Results from the Forced Vital Capacity Test (% of Predicted) | |||||||
| Mean ± SD | 55.3 ± 15.9 | 58.7 ± 19.3 | 3.4 ± 10.0 | 55.6 ± 12.3 | 56.3 ± 15.7 | 0.8 ± 9.6 | 2.7 ± 2.5c 4.3 ± 2.3d (p=0.07) |
| Median | 54.9 | 59.2 | 2.1 | 57.4 | 54.6 | -2.5 | |
| Percentiles (25th, 75th) | 43.6, 69.3 | 44.4, 70.7 | -0.8, 9.5 | 46.9, 64.4 | 43.8, 67.5 | -5.4, 5.0 | |
| a One patient in the placebo group and one patient
in the ELAPRASE group died before Week 53; imputation wasby last observation
carried forward in the intent-to-treat analysis b Change, calculated as Week 53 minus Baseline c Observed mean ± SE d ANCOVA model based mean ± SE, adjusted for baseline disease severity, region, and age. |
|||||||
Measures of bioactivity were urinary GAG levels and changes in liver and spleen size. Urinary GAG levels were elevated in all patients at baseline. Following 53 weeks of treatment, mean urinary GAG levels were markedly reduced in the ELAPRASE weekly group, although GAG levels still remained above the upper limit of normal in half of the ELAPRASE-treated patients. Urinary GAG levels remained elevated and essentially unchanged in the placebo group. Sustained reductions in both liver and spleen volumes were observed in the ELAPRASE weekly group through Week 53 compared to placebo. There were essentially no changes in liver and spleen volumes in the placebo group.
Generic Name: Idursulfase Solution
- « Previous
- Clinical Pharmacology
- Next »
Women's Health
Find out what women really need.
Herbal First Aid
Herbal medicine is ancient, but only in recent years have many people started to take notice of its all natural healing powers. See more WebMD Videos »
